These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2011-004651-40||A multi-center, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bortezomib and dexamethasone (VD) in previo...||2015-09-30||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2011-004672-11||A multi-centre, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bendamustine and rituximab (BR) in previous...||2017-04-27||bad-data|
|Reported results||2011-005710-11||A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.||2013-12-03||due-trials|
|Reported results||2012-001525-27||Phase IIa study to characterize the effects of the Spiegelmer® NOX H94 on anemia of chronic disease in patients with cancer||2013-12-30||due-trials|
|Reported results||2013-003585-14||Safety, PK/PD and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anaemia: A randomized, double blind, placebo controlled parallel group study with a single blind cross-over group||2015-11-16||due-trials|
|Exempt||2016-003657-15||A Two-Part, Open-Label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in M...||not-yet-due|
|Exempt||2018-004064-62||Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Pr...||not-yet-due|